ANRO ANRO
Company Profile ↓Company Overview
ANRO (ANRO) is a publicly traded company listed on with a market capitalization of $894.82M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.16.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +816.01% |
| 6 Months: | +73.45% |
| 3 Months: | +10.14% |
| 1 Month: | +9.07% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)56.77 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -7.20M | -9.12M | -9.72M | -14.39M | -18.34M | -18.89M | -15.68M | -18.68M | -14.95M | -27.14M |
| Net Income | -7.28M | -8.66M | -9.14M | -13.42M | -16.03M | -16.78M | -15.17M | -17.71M | -14.18M | -26.24M |
| Diluted EPS | -1.97 | -2.33 | -2.44 | -0.76 | -0.60 | -0.62 | -0.56 | -0.65 | -0.52 | -0.80 |
| R&D Expense | 5.61M | 7.07M | 7.97M | 9.95M | 13.18M | 13.06M | 9.97M | 13.12M | 10.53M | 20.29M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 27.45M | 37.81M | 68.61M | 66.36M |
| Operating Income | - | -27.45M | -37.81M | -68.61M | -66.36M |
| EBITDA | - | -27.37M | -34.56M | -59.55M | -60.11M |
| Interest Expense | - | 0 | 1.37M | 1.38M | 2.47M |
| Pretax Income | - | -27.71M | -36.30M | -61.43M | -63.24M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -27.71M | -36.30M | -61.43M | -63.24M |
| Diluted EPS | - | -2.13 | -1.42 | -2.50 | -2.19 |
| R&D Expense | - | - | 30.29M | 47.00M | 45.62M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 50.85M | 86.63M | 177.54M | 184.69M |
| Current Assets | - | 49.22M | 85.39M | 169.34M | 177.72M |
| Cash & Equivalents | - | 48.34M | 82.55M | 168.23M | 176.48M |
| Inventory | - | - | - | - | - |
| Receivables | 1.50M | 333.00K | - | - | - |
| Total Liabilities | - | 89.26M | 158.30M | 26.08M | 33.55M |
| Current Liabilities | - | 5.56M | 5.61M | 10.01M | 11.32M |
| Long Term Debt | - | 9.46M | 9.86M | 11.56M | 18.40M |
| Total Debt | - | 9.75M | 9.99M | 16.94M | 23.96M |
| Total Equity | - | -38.41M | -71.67M | 151.46M | 151.14M |
| Shares Outstanding | - | 25.57M | 25.57M | 26.99M | 31.92M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -20.39M | -33.45M | -47.42M | -51.77M |
| Investing Cash Flow | - | -732.00K | -470.00K | -2.08M | -24.00K |
| Financing Cash Flow | - | 43.79M | 68.13M | 135.69M | 60.08M |
| Capital Expenditure | - | -732.00K | -470.00K | -2.08M | -24.00K |
| Free Cash Flow | - | -21.13M | -33.92M | -49.50M | -51.79M |
| Net Change in Cash | - | 22.66M | 34.21M | 86.19M | 8.29M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | 72.2% | 50.7% | -40.6% | -41.8% |
| ROCE % | - | -60.6% | -46.7% | -41.0% | -38.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ANRO
ANRO Stock Drops 7% After Disappointing Schizophrenia Study Results – But Analyst Sees Dip As Attractive Entry Point - Stocktwits
<a href="https://news.google.com/rss/articles/CBMihgJBVV95cUxOVnRBQ0RnWmVaLUJZMTZBYUFKa0o5ZHFNdnhZUFVtNEx5R1J4cDFKSWlnVFNMZ1JxVmpGWFBPN3VmWklWLTNrNGZhVkhMRXdwQkhPZU1yTl81SHVHQ3JIUXhHbHVXOFE0czZvNjZ0NFlPc2RHaWl0YlZRZkVzazJUMC1QaFJzQjYzZ0FIUW…
Is Alto Neuroscience, Inc. (ANRO) Stock Positioned for Growth With New Insights Into Anhedonia Treatment? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQY0xqTDREU3BweUpZTnVrT0x1QmJJaTB6cWpKV1kyUUlqZ2JDNUx3d21JY1Z5SnhCR2hZRzJ6UmFTWGp4dWZnYnNXOHd3LVl6Y1NQQlFONjJDWVJSZXE5N2NkanJzXzh6VVNTUnFTV3MzMlRNZ0dRblRYb2hDeW9CbXA3QmR0cjZudUN3U2…
Alto Neuroscience: Buy ALTO-207 Advancement TRD And Other Expansion Indications (ANRO) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPdmdVaEw0cmtDOVIzR3hDenMwR1pZbG1YSlFQZ2NUYzhMZHo3cG12b1dyNFJiaGVPN3NuaUJqNEVkd0pCaW1VbmNMcVRhSm55LS1oUlBVakFKanRLOUhQUG9BQ2t6R1lONGZSOHAxSDFDNjZSRWhyZFg0UldyWG1vLXZrU3ZfMHJsT2tSOU…
BlackRock, Inc. Expands Stake in Alto Neuroscience Inc (ANRO) wi - GuruFocus
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxPQXJQT0hrTW5IY0VKWlEwOWtKckgteF9mRWl3TWZpQkFMeTVBdmxaQ09HbTBvdTYzajJ5WFhuSTY3WjNfMmVvVGtnSzBKNnEwbkZJcHlmT0ppT2VYUkkwMDhlWDRSUWE5a1dkNW9GeldvWl95cWRDM1J3MlFNbGxucmMzRzZtRXM0blRzTD…
BlackRock (ANRO) discloses 6.0% beneficial ownership in Alto Neuroscience common stock - Stock Titan
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxNWm5od2Z5Mkt6TldWTWZZeWVHNDJmTWZZeUQxUEFXXzlfZy1xTkNGaG1ZTVdCVXRlSHlBQmstcVZzU012ME5paVh0akd1OGxVUkM3YUdRbEpMVlJRTUNXS1o5YWRCN2RVZmtxMEd5RDI3UkxqdVp3cTA3NW04Z0FBTkQ4ZlZYMkdoZEp1Vn…
Alto Neuroscience Stock Pre-Market (-7.0%): Geopolitical Tensions Spark Risk-Off Move - Trefis
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxQN1RiTTRCYWJuWmFqWTZYZ051UVNhbnRoQ1dORTBjSjYtbXUtM0R6U0lhQXZHTUgzUG9mb1phNldYbmgwOFZwRXU0VE5tbHJSME5pdHAzMTVCZ0NjVTVDSlB2Y05sa0xURWpLSkE4MzRlbWlGTjlyTzZkNFB0UUNHdTkxUzdpYlJOcE5RUG…
ANRO — Frequently Asked Questions
What is the current share price of ANRO?
As of 2026-08-05 17:25 PDT, ANRO trades at $28.03 on NASDAQ/NYSE. Its 52-week range is $3.06 to $28.63.
What is the market capitalisation of ANRO?
ANRO has a market capitalisation of $894.82M on NASDAQ/NYSE.
What is the P/E ratio of ANRO?
ANRO trades at a trailing price-to-earnings (P/E) ratio of -12.80. Its price-to-book (P/B) ratio is 5.92.
What is the return on equity (ROE) of ANRO?
ANRO has a return on equity (ROE) of -41.84%. Its return on capital employed (ROCE) is -38.28%.
Is ANRO a good stock to buy?
This page provides a data-driven analysis of ANRO, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.